STM JOURNALS

International Journal of
Biochemistry and Biomolecules Research

Volume 3, Issue 1, 2025
January—June
DOI (Journal): 10.37591/IJBBR

https://journals.stmjournals.com/ijbbr

Review IJBBR

Formulation Development and Evaluation Technique for Immediate and Modified Release Capsule

Mohd. Wasiullah[1], Piyush Yadav[2], Deepak Yadav[3,*], Vinay Kumar Yadav[4]

Abstract

The development and evaluation of formulations for immediate-release (IR) and modified-release (MR) capsules represent a critical aspect of pharmaceutical dosage form design, offering distinct advantages in terms of drug release profiles and therapeutic outcomes. This study focuses on the formulation strategies, techniques, and evaluation methods used to develop both IR and MR capsules. Immediate-release capsules are designed to disintegrate quickly in the gastrointestinal tract, ensuring rapid drug absorption, while modified-release capsules are engineered to control the release of the active pharmaceutical ingredient (API) over an extended period or at specific sites within the digestive system. For the IR capsules, the formulation development process typically involves the selection of suitable excipients, such as disintegrants, fillers, and lubricants, to achieve rapid dissolution. In contrast, MR capsules often incorporate rate-controlling mechanisms, such as polymers, coatings, or matrix systems, which allow for sustained or delayed release. The evaluation of both types of capsules is carried out through a combination of in vitro tests including dissolution testing, disintegration time, and stability studies, alongside in vivo bioavailability studies to assess the therapeutic efficacy and safety of the drug.

Keywords: Modified release, capsule formation, drug delivery, polymers, pharmaceutical excipients

INTRODUCTION

The development of oral capsules, especially for immediate and modified release, is an essential focus in pharmaceutical formulation. Capsules offer a versatile and patient-friendly dosage form that can protect active ingredients and provide controlled or immediate drug delivery. Immediate-release (IR) capsules are designed to rapidly release the drug upon ingestion, delivering an immediate therapeutic effect. Modified release (MR) capsules, on the other hand, are engineered to release the active ingredients at a controlled rate, either to delay the onset of action or to maintain a therapeutic effect over an extended period. Effective formulation and evaluation techniques are critical to achieving these release profiles, as they ensure drug stability, bioavailability, and desired therapeutic effects. The development involve capsules involves a careful selection of excipients, design of release mechanisms, and optimization of manufacturing processes. Key techniques include pre-formulation studies, formulation optimization, in vitro and in vivo evaluation, and stability testing [1].

This introduction will explore the formulation development and evaluation techniques for immediate and modified-release capsules, focusing on critical parameters, such as dissolution rates, release mechanisms, and evaluation methodologies to meet therapeutic goals and regulatory standards (Figure 1).

***Author for Correspondence**
Deepak Yadav
E-mail: ydeepak941@gmail.com

1Principal, Department of Pharmacy, Prasad Institute Technology, Jaunpur, Uttar Pradesh, India
2Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
3Lecturer, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
4Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India

Received Date: December 14, 2024
Accepted Date: December 21, 2024
Published Date: February 13, 2025

Citation: Mohd. Wasiullah, Piyush Yadav, Deepak Yadav, Vinay Kumar Yadav. Formulation Development and Evaluation Technique for Immediate and Modified Release Capsule. International Journal of Biochemistry and Biomolecule Research. 2025; 3(1): 1–9p.
DOI: https://doi.org/10.37591/IJBBR.v03i01.198198



Figure 1. Comparison of immediate-release (IR) and dual delayed-release (DDR) formulations: design and plasma concentration profiles.

MATERIAL & METHODS

Formulation Development

a. *Selection of Active Pharmaceutical Ingredient (API):* API Characteristics: The choice of API is critical. It should have suitable solubility and permeability to ensure effective absorption in the gastrointestinal
b. *Excipients Fillers/Binders:* Microcrystalline cellulose, lactose, starches (e.g., maize starch), or mannitol are commonly used for capsule filling [2].
c. *Capsule Shell Selection:* Capsules can be made from gelatine or plant-based materials (e.g., HPMC). The size and type of capsule (hard or soft) are determined based on the desired dosage and API characteristics.
d. *Dosage Form Design:* Decide the appropriate strength (mg of API per capsule). Determine the release profile (for immediate release, the aim is fast disintegration in the stomach) (Figure 2).



Figure 2. Schematic representation of enteric capsule design for air-entrapped carbopol formulation, showing drug release mechanism aimed at controlled disintegration.

Formulation Techniques

a. *Dry Granulation:* This method is suitable when the API is sensitive to moisture or heat. It involves blending the API and excipients, followed by compacting the powder into slugs or briquettes, which are then milled into granules for capsule filling.

b. *Wet Granulation:* Involves using a liquid binder (e.g., water, alcohol) to form a granulate. The mixture is dried and screened to the required size for capsule filling. It's often used for poorly compressible or hygroscopic drugs [3].
c. *Direct Compression:* For APIs that are compressible and do not require additional processing, direct compression is used to compress the powdered blend into tablets or capsules directly. This is the simplest and fastest method.
d. *Spheronization:* For high-dose formulations or APIs that require uniform release, the granules may be spheronized to form round pellets (Figure 3).



Figure 3. Comparison of EDPC and DC processes for film and capsule formation.

EVALUATION TECHNIQUES

Preformulation Studies

a. *Solubility and Dissolution:* Understanding the solubility profile of the API in various media is crucial for IR and MR formulations. Solubility studies guide the choice of excipients, as well as the need for any solubilizers or pH modifiers.
b. *Compatibility Studies:* Evaluating compatibility between the API and excipients helps in selecting materials that won't affect the stability or release characteristics of the formulation.
c. *pKa Determination:* The ionization constant (pKa) of a drug influences its solubility, permeability, and absorption.
d. *Partition Coefficient (log P):* This helps predict how the drug will distribute between aqueous and lipid phases, affecting absorption [4].
e. *Melting Point Analysis (Thermal Analysis):* Techniques, such as DSC (differential scanning calorimetry) and TGA (thermogravimetric analysis) provide insight into drug stability and help select compatible excipients.
f. *Polymorphism Screening:* Different polymorphic forms can impact the release rate, solubility, and stability of the drug [5].

Dissolution Profiling

a. *Immediate-Release Capsules:* The dissolution profile is critical to ensure the rapid release of the API. It's tested in a dissolution medium simulating the stomach environment, often aiming for at least 85% release within 15–30 minutes. This is assessed using a USP apparatus (paddle or basket).
b. *Modified-Release Capsules:* Dissolution profiling for MR capsules is more complex, often using multiple media to simulate the pH changes through the gastrointestinal tract (e.g., acidic for the stomach, neutral for the intestine). The profile assesses how well the formulation controls release over time and is analyzed to see if it follows desired kinetics (e.g., zero-order, first-order).3. Drug release mechanism studies.

Release Kinetics Models

Various mathematical models (e.g., zero-order, first-order, Higuchi, Korsmeyer-Peppas) help in understanding the drug release kinetics for MR capsules. The model that best fits the release data can provide insights into the mechanism (diffusion, erosion, swelling, etc.).

a. *Swelling and Erosion Studies (for MR):* If the MR formulation uses polymers for controlled release, studies to evaluate swelling and erosion are conducted. This helps in understanding the release mechanism and how the formulation will behave over time [6].

Disintegration Testing

a. *Immediate-Release Capsules:* Disintegration tests measure the time taken for the capsule to break down in a dissolution medium. IR capsules need to disintegrate quickly (typically within a few minutes).
b. *Modified-Release Capsules:* For delayed-release or extended-release capsules, disintegration testing may involve different pH environments to verify the capsule's stability and behavior in the stomach or intestine. In some MR formulations, disintegration might not be required if the capsule is designed to release the drug over a prolonged period without breaking down.

Uniformity Testing

a. *Content Uniformity:* Ensuring uniform API distribution across capsules is essential. This involves sampling capsules to check API concentration in each unit, which is particularly critical for low-dose and MR formulations [7].
b. *Weight Variation:* Each capsule's weight is checked to confirm the proper fill, especially for MR capsules, where excipient ratios influence the release profile.

IN VITRO-IN VIVO CORRELATION (IVIVC) STUDIES

Modified-Release Capsules

IVIVC studies aim to correlate in-vitro release data with in-vivo absorption data. Developing IVIVC models in the early stages helps predict how the drug will behave in humans and assists in adjusting the formulation to achieve the desired release profile [8, 9].

Stability Studies

a. *Accelerated Stability Testing:* IR and MR formulations undergo stability testing under accelerated conditions (e.g., high temperature and humidity) to predict shelf life [10].
b. *Long-Term Stability Testing:* Long-term stability testing helps confirm the release characteristics and overall quality over time, particularly for MR formulations to ensure consistent release rates.

Specialized Testing for MR Capsules

a. *Lag Time Evaluation:* For delayed-release formulations, the capsule is tested for "lag time," the time before the drug begins to release. This is often tested in acidic media to simulate gastric conditions before moving to neutral media [11–13].
b. *Burst Release Testing:* Some MR formulations undergo testing to ensure there isn't an unintended initial "burst" release of the drug, which could affect safety and efficacy.
c. *Simulated Gastrointestinal Tract (GIT) Conditions:* Testing in media that simulate various parts of the GIT (different pH levels, enzyme presence) is critical for MR formulations designed to release at specific GI locations [14].

Optimization and Scale-Up Studies

a. *Process Optimization:* Variables, such as mixing time, filling, and encapsulation conditions are adjusted to ensure batch consistency and reproducibility.
b. *Pilot Scale Trials:* Small-scale production trials help ensure that the formulation performs as expected on a larger scale, especially for MR capsules where minor formulation changes can impact the release rate [15–17].

These evaluation techniques guide formulation scientists in developing IR and MR capsules that meet the desired therapeutic profile, ensure batch-to-batch consistency and comply with regulatory standards (Figure 4).



Figure 4. pH-sensitive polymer-coated drug delivery to the colon.

Quality Control and Regulatory Considerations

Ensure compliance with pharmacopoeial standards (e.g., USP, EP) for capsule appearance, content uniformity, dissolution, and disintegration. Perform validation studies to demonstrate that the formulation meets consistency, efficacy, and safety standards [18–21].

Final Release Profile Evaluation

For immediate-release capsules, the goal is to achieve rapid dissolution in the stomach. A typical dissolution profile should show: *Fast release:* >80% of the drug should be released within 30 minutes (for most immediate-release formulations). By carefully selecting the right excipients, optimizing the manufacturing process, and rigorously evaluating the product, the formulation of immediate-release capsules can be successfully developed to meet regulatory and patient needs [22, 23].

PROCEDURE

Developing modified-release and immediate-release capsules involves distinct steps tailored to achieve their unique release:

Immediate-Release Capsules

a. *Formulation Design:* Select excipients that dissolve rapidly in the gastrointestinal tract to ensure Blending quick release and absorption of the active pharmaceutical ingredient (API).
b. *Mixing:* Ensure uniform mixing of the API and excipients [24–26].
c. *Encapsulation:* Fill the capsule shells with the blended mixture.
d. *Evaluation:* Test for drug content uniformity, dissolution rate, and disintegration time to confirm quick release.

Modified-Release Capsules

a. *Formulation Design:* Choose techniques like coating, embedding in a matrix, or using hydrophilic/hydrophobic excipients to control the release rate [27, 28].
b. *Granulation or Layering:* Granulate or layer the API to achieve a sustained release profile.
c. Encapsulation: Place the modified-release formulation in capsule shells.
d. *Coating (Optional):* Apply a polymer coating to control the release rate further.
e. *Evaluation:* Conduct dissolution tests to confirm the release profile, content uniformity, stability studies, and in vitro-in vivo correlation (IVIVC) to predict in vivo behavior [29, 30].

Both formulations undergo rigorous testing to ensure they meet the desired release profiles and regulatory standards.

CHALLENGES AND FUTURE PROSPECTS

Challenges

Stability Issues

a. *API Stability:* Many drugs, especially sensitive molecules (e.g., proteins, peptides, and certain vitamins), may degrade quickly in the acidic environment of the stomach. Stabilizing such drugs in an ICR formulation can be difficult.
b. *Formulation Stability:* The encapsulation material must ensure that the capsule remains intact during storage and handling but releases the drug promptly once ingested [31].

Gastrointestinal (GI)

The rate and extent of drug absorption can vary significantly from person to person due to differences in gastric pH, motility, and enzyme levels. ICR formulations may be less predictable across diverse patient populations.

Dose Uniformity

Ensuring uniformity in the release of the active ingredient from the capsule can be challenging, especially for drugs that have a narrow therapeutic window. Over or under-dosing can have serious clinical consequences.

Solubility and Dissolution

Drugs that are poorly soluble in water can face challenges in ICR formulations because they may not dissolve fast enough for efficient absorption. Enhancing the solubility of such drugs is critical, which often involves complex excipient or formulation strategies [32].

Patient Compliance

Immediate-release formulations can lead to spikes in plasma drug concentration, which may cause side effects, especially with drugs that have a narrow therapeutic index. This might affect patient adherence to treatment regimens.

Manufacturing Complexity

Producing capsules with consistent performance can be challenging, especially when incorporating sensitive or high-dose drugs. This often requires sophisticated manufacturing techniques and stringent quality control.

Regulatory and Developmental Hurdles

The regulatory requirements for ICR formulations can be complex, particularly for new drug types or novel delivery technologies. Meeting safety, efficacy, and quality standards while also addressing the need for faster development timelines can strain resources.

FUTURE PROSPECTS OF IMMEDIATE CAPSULE RELEASE

Advanced Drug Delivery Technologies

a. *Nanotechnology:* Nanocarriers, such as nanoparticles, liposomes, or solid lipid nanoparticles, may help improve the stability and solubility of drugs, enabling more controlled and efficient immediate release.
b. *Microencapsulation:* The use of advanced microencapsulation technologies can help protect sensitive drugs and allow for more precise release profiles, even in ICR formulations.
c. *Smart Capsules:* Future capsules may include embedded sensors or triggers that respond to environmental cues (e.g., pH, temperature, or enzymatic activity) to release drugs at optimal rates.

Personalized Medicine

The future of ICR could involve more tailored formulations that account for individual differences in drug absorption and metabolism. Personalized dosing, potentially aided by pharmacogenomics, could improve the safety and efficacy of immediate-release formulations.

Improved Formulation Techniques

The development of better excipients and formulation strategies can help overcome solubility and stability challenges, making ICR formulations more feasible for a broader range of drugs, including biologics and poorly soluble compounds.

Combination Therapies

ICR capsules could be designed to deliver multiple drugs simultaneously, which is particularly useful for combination therapies (e.g., for cancer or HIV treatment). Technologies, such as co-crystal formation or layered capsule systems could enable this.

Sustainable and Cost-Effective Manufacturing

Innovations in manufacturing techniques, such as 3D printing and continuous manufacturing, may improve the scalability and cost-effectiveness of ICR formulations, making them more accessible to a broader range of patients and diseases.

Regulatory Flexibility

As regulators become more familiar with advanced drug delivery systems, there may be greater flexibility in how ICR formulations are approved. This could help accelerate the time-to-market for new drugs with immediate release profiles.

Biologics and mRNA Delivery

Immediate-release systems are being explored for biological drugs, including mRNA-based therapies, where rapid onset of action is required. Innovations in capsule design could enable effective and stable delivery of these large, sensitive molecules.

CONCLUSIONS

Developing and evaluating formulation techniques for immediate and modified-release capsules requires a comprehensive approach that balances therapeutic efficacy, patient compliance, and manufacturing feasibility. Immediate-release formulations aim to deliver the active pharmaceutical ingredient (API) promptly, ensuring rapid onset of action. This is particularly beneficial for medications that require quick relief, such as painkillers or antipyretics. However, modified-release formulations are designed to control the release of the API over an extended period, offering advantages in sustained drug levels and reduced dosing frequency, which can enhance patient adherence and reduce side effects. Key steps in formulation development include selecting appropriate excipients, designing a suitable release mechanism (e.g., matrix or coating), and optimizing capsule characteristics like dissolution rate and bioavailability. Evaluation techniques involve in vitro dissolution testing, stability studies, and in vivo pharmacokinetics to assess release profiles and predict therapeutic outcomes. Advanced methods, such as quality by design (QbD) and design of experiments (DoE) enable a systematic approach, identifying critical quality attributes and process parameters that influence product performance. Ultimately, a successful formulation balances immediate and modified-release properties to meet specific therapeutic goals while maintaining quality, efficacy, and safety. Ongoing innovations in capsule design, coupled with rigorous evaluation techniques, are essential in meeting diverse patient needs and advancing the development of tailored drug delivery systems in the pharmaceutical field.

REFERENCES

1. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6):e17488.

2. Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. J Control Release. 2022;342:53–65.
3. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905.
4. Tanwar H, Sachdeva R. Transdermal drug delivery system: A review. Int J Pharm Sci Res. 2016;7(6):2274.
5. Gupta P, Gnanarajan PK, Kothiyal P. Floating drug delivery system: a review. Int J Pharma Res Rev. 2015;4(8):37–44.
6. Gaikwad SS, Ainor SK, Lande NB, Salunkhe KS. Review of modified oral solid drug delivery system and recent active patents. Appl Drug Res Clin Trials Regulatory Affairs. 2022;9(1):20–29.
7. Sharma A, Saini S, Rana AC. Transdermal drug delivery system: a review. Int J Res Pharm Biomed Sci. 2013;4(1):286–292.
8. Dhiman S, Singh TG, Rehni AK. Transdermal patches: a recent approach to new drug delivery system. Int J Pharm Pharm Sci. 2011;3(5):26–34.
9. Mali AD. An updated review on transdermal drug delivery systems. Skin. 2015;8(9):244–254.
10. Parivesh S, Sumeet D, Abhishek D. Design, evaluation, parameters and marketed products of transdermal patches: A review. J Pharm Res. 2010;3(2):235–240.
11. Saroha K, Yadav B, Sharma B. Transdermal patch: A discrete dosage form. Int J Curr Pharm Res. 2011;3(3):98–108.
12. Kumar A, Machhindra KS, Jain K, Yadav AK. Transdermal drug delivery system. Novel Carrier Systems for Targeted and Controlled Drug Delivery. Singapore: Springer Nature Singapore; 2024. 115–133.
13. Alkilani AZ, Nasereddin J, Hamed R, Nimrawi S, Hussein G, Abo-Zour H, et al. Beneath the skin: a review of current trends and future prospects of transdermal drug delivery systems. Pharmaceutics. 2022;14(6):1152.
14. Bhowmik D, Pusupoleti KR, Duraivel S, Kumar KS. Recent approaches in transdermal drug delivery system. Pharm Innov. 2013;2(3, Part A):99.
15. Bala P, Jathar S, Kale S, Pal K. Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery. J Pharm Res. 2014;8(12):1805–1835.
16. Yadav V. Transdermal drug delivery system. Int J Pharm Sci Res. 2012;3(2):376.
17. Wiedersberg S, Guy RH. Transdermal drug delivery: 30+ years of war and still fighting! J Control Release. 2014;190:150–156.
18. Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Aging. 2008;25:269–280.
19. Guy RH. Transdermal drug delivery. Drug Deliv. 2010:399–410.
20. Sadeghi F, et al. Modified release formulations: development and evaluation techniques. J Control Release. 2017;260:40–51.
21. Venkatesh DK, et al. Development of controlled release formulations of poory soluble drugs. Drug Devel Ind Pharm. 2011;37(10):1214–1220.
22. Singh SP, et al. Formulation and evaluation of modified release capsules for the treatment of chronic conditions. Int J Pharm Sci. 2018;10(5):376–386.
23. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175–187.
24. Bird D, Ravindra NM. Transdermal drug delivery and patches—An overview. Med Devices Sens. 2020;3(6):e10069.
25. Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Patents Drug deliv Formul. 2009;3(2):105–124.
26. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3(2):115–124.
27. Sabbagh F, Kim BS. Recent advances in polymeric transdermal drug delivery systems. J Control Release. 2022;341:132–146.

28. Alam MI, Alam N, Singh V, Alam MS, Ali MS, Anwer T, et al. Type, preparation and evaluation of transdermal patch: a review. World J Pharm and Pharm Sciences. 2013;2(4):2199–2233.
29. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today. 2004;9(16):697–703.
30. Rastogi V, Yadav P. Transdermal drug delivery system: An overview. Asian J Pharma (AJP). 2012;6(3).
31. Jeong WY, Kwon M, Choi HE, Kim KS. Recent advances in transdermal drug delivery systems: A review. Biomater Res. 2021;25(1):24.
32. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv. 2004;1(1):81–92.

